Connect with us

Hi, what are you looking for?

Oracle of  Omaha Says – Investing and Stock NewsOracle of  Omaha Says – Investing and Stock News

Editor's Pick

Novavax stock price volatility crashes amid existential risks

Novavax (NASDAQ: NVAX) stock price has dropped in the past five straight days as concerns about the company’s outlook darkened. The shares were trading at $7.65, which was about 32% below this month’s high of $11.31. At its peak, NVAX shares were trading at $330.

Novavax faces two key risks

Novavax was one of the top beneficiaries of the Covid-19 pandemic. The company’s revenue jumped from over $18.7 million in 2019 to more than $475 million in 2020. Its revenue blasted to over $1.9 billion in 2022.

Its losses also jumped. The company’s net loss jumped from $132 million in 2019 to over $1.73 billion in 2022. This increase happened as the company boosted its investments in its Covid vaccine rollout.

The most recent results showed that the company’s revenue dropped by 88% to $81 million in the first quarter as demand. Its net loss jumped to more than $294 million compared to over $203 million in the same quarter in 2022. 

Novavax hopes that its total revenue will be between $1.4 billion and $1.6 billion. It also hopes that its cash flow in the second and third quarters will be about $500 million. 

The biggest risk for Novavax is that it has billions in orders from several governments. Governments have over $2.1 billion in advance purchases from governments. With the Covid-19 pandemic having ended, and with demand for vaccines falling, there is a likelihood that many of these governments will not honor their commitments. In a statement to FT, the company’s CEO said:

“And then to all of a sudden say: ‘Well you spent all your money, you committed to protect our citizens. Now we don’t think we need it as much. Sorry, you’re out of luck.’ That’s probably not good for long-term relationships and that type of thing and to benefit public health,

The other risk for the company is that it does not have a strong pipeline of vaccines. This is in contrast to a company like Moderna which has several vaccines in development.

Novavax stock price forecast

The weekly chart shows that the NVAX share price has been in a freefall for a long time and is now sitting at the lowest level since 2020. The Average True Range (ATR) has crashed to a low of 2.84, the lowest point since May 2020. This is one of the most popular volatility indicators.

Novavax shares have moved below all moving averages. Therefore, the stock could continue falling as sellers attempt to move below the key support at $2. This view can only change if the cash-strapped company confirms its deals with governments.

The post Novavax stock price volatility crashes amid existential risks appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Editor's Pick

    Everynet, one of the world’s largest network operators for national LoRaWAN® networks, announces it is working with Amazon Web Services (AWS) to offer long-range...


    As more candidates throw their hats into the 2024 Presidential ring, I’d like to offer a proposal that should have immediate bipartisan support: stop...

    Editor's Pick

    The Internet of Things (IoT) is changing the way we interact with technology, and it has the potential to revolutionize the way we manage...

    Editor's Pick

    Semtech Corporation and esteemed engineering design services firm, Connected Development, today announced the launch of the new XCVR Development Board and Reference Design integrating...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2023